Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 2, 2010


RainDance Technologies has appointed Richard Lussier as vice president of worldwide sales and Ingrid Choupin as managing director of European sales and marketing.

Lussier joins RainDance from Cell Biosciences where he was the VP of worldwide sales and service. He also held sales positions at Solexa (now Illumina), Fluidigm, Applied Biosystems (now part of Life Technologies), and Celera Genomics. He holds a BSc in biology from Rhode Island College and an MBA from the Fox School of Business at Temple University.

Choupin most recently was associate director of global sales and strategy development at Affymetrix. Prior to joining Affy in 2002, she held various sales and management positions at Invitrogen (now part of Life Technologies). Choupin holds an MSc in biochemistry from the Université d’Orsay in Paris and a marketing management degree from the Institut Superieur De Gestion, also in Paris. Choupin will be based in France.

Signal Genetics has appointed five people to serve on its scientific advisory board: Kenneth Anderson, Keith Stewart, David Gelfand, Cynthia French, and Craig Keyes.

Anderson is director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute and Kraft Family professor of medicine at Harvard Medical School; Keith Stewart is professor of medicine at the Mayo Clinic; Gelfand is chief scientific officer at WaferGen Biosystems, has worked previously at Roche Molecular Systems, and he is an inventor of Taq DNA polymerase; French recently was chief scientific officer at Exiqon and she has worked at Affymetrix and Quest Diagnostics; Keyes was president and CEO of UnitedHealthcare of Colorado and CEO of UnitedHealthcare of New York Tri-State, among other management positions.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more